Duchenne Muscular Dystrophy Market Updates

Global Duchenne Muscular Dystrophy Market size was valued at USD 2.1 billion in 2023 and is poised to grow from USD 2.34 billion in 2024 to USD 5.64 billion by 2032, growing at a CAGR of 11.6% during the forecast period (2025-2032).

Global duchenne muscular dystrophy market is competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Pfizer Inc. (US) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'Mylan N.V. (US) ', 'Fresenius Kabi AG (Germany) ', 'Hikma Pharmaceuticals plc (UK) ', 'Novartis AG (Switzerland) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Bristol Myers Squibb Company (US) ', 'GSK plc (UK) ', 'Bayer AG (Germany) ', 'Sun Pharmaceutical Industries Ltd. (India) ', 'Boehringer Ingelheim (Germany) ', 'Sanofi (France) ', 'Sarepta Therapeutics, Inc. (US) ', 'Aurobindo Pharma (India) ', 'Capricor Therapeutics, Inc. (US) ', 'Catalyst Pharmaceuticals Inc (US) ', 'EspeRare Foundation (Switzerland) ', 'FibroGen, Inc. (US) ', 'Italfarmaco S.p.A (Italy)'

Prevalence of duchenne muscular dystrophy is on the rise, and factors that are driving its market growth include increased awareness campaigns about the disorder, the development of mutation-specific therapies, the rise in product pipelines, the introduction of therapies like Exondys51 and Translarna, and the use of corticosteroid-based anti-inflammatory drugs.

The introduction of novel pharmaceuticals and treatments, disease-modifying treatments, significant backing from numerous firms for drug research, and support from patient advocacy groups on the regulatory approval process are the main factors driving the global market for duchenne muscular dystrophy.

North America dominated the global duchenne muscular dystrophy market. The market in North America is expected to expand as a result of a number of important factors, including the rising prevalence of muscular dystrophy in the region, FDA drug approval, strong healthcare infrastructure supported by supportive government regulations, and medical reimbursement in the region and due to anticipated product launches.